Study findings could provide blueprint for regulating lab-developed diagnostic tests
The FDA’s policy deviations specific to COVID tests might be employed in ongoing oversight of all such tests.
Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
Dr. Lennerz is board certified by the American Board of Pathology and the American Board of Medical Genetics. He joined the Massachusetts General Hospital Department of Pathology and Center for Integrated Diagnostics as a staff pathologist in 2014, and is an assistant professor at Harvard Medical School. Dr. Lennerz trained as a pathologist assistant in Berlin, Germany in 1994 and studied both medicine and molecular medicine at the University of Erlangen, Germany where he also received his MD and PhD. He completed his residency training in anatomic pathology in 2008, and a fellowship in molecular genetic pathology in 2009 at Washington University in St. Louis, MO. After completing a two-year gastrointestinal and liver pathology fellowship at Massachusetts General Hospital in 2011, he led a research group on biomarkers in lymphoma at Ulm University, Germany. His interests are tissue-based biomarkers, and financial sustainability of molecular genetic diagnostics. . Early in 2015 Dr. Lennerz joined the Cancer Center's physician staff at Mass General, and began presenting at the Cancer Center Grand Rounds.
Clinical Interests:
Treats:
Languages:
Mass General Pathology
55 Fruit St.
Boston, MA 02114
Phone: 617-643-0800
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Lennerz has research interests in tissue-based biomarkers in cancer, digital pathology, and migraine-pain research.
Recent:
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is the #1 Research Hospital in America and recognized in 14 specialties assessed by U.S. News & World Report.
The FDA’s policy deviations specific to COVID tests might be employed in ongoing oversight of all such tests.
Legislation under consideration in U.S. Congress would increase regulatory oversight of certain diagnostic tests, and a new study by researchers at MGH and colleagues from several other institutions demonstrates that its impact will depend on key details in the bill’s final language.
Odontoblasts, the cells that form a tooth’s dentin, have a newly discovered function: sensing cold, which can trigger pain in teeth. But scientists have also found a way to block the pathway to cold-sensitive teeth.
Drugs that inhibit the protein expressed by a mutated form of the KRAS gene might soon be approved, but cancer cells often develop additional mutations that make them resist such targeted drugs. Investigators have identified some of these mutations in a patient and strategies to overcome them.